Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Taxes (2021 - 2025)

Collegium Pharmaceutical (COLL) has 5 years of Current Taxes data on record, last reported at $797000.0 in Q3 2025.

  • For Q3 2025, Current Taxes fell 25.23% year-over-year to $797000.0; the TTM value through Sep 2025 reached $797000.0, down 25.23%, while the annual FY2024 figure was $8.5 million, 299.11% up from the prior year.
  • Current Taxes reached $797000.0 in Q3 2025 per COLL's latest filing, up from $328000.0 in the prior quarter.
  • Across five years, Current Taxes topped out at $14.1 million in Q1 2024 and bottomed at $36000.0 in Q3 2021.
  • Average Current Taxes over 5 years is $3.3 million, with a median of $931500.0 recorded in 2024.
  • Peak YoY movement for Current Taxes: skyrocketed 299.11% in 2024, then crashed 38.35% in 2025.
  • A 5-year view of Current Taxes shows it stood at $622000.0 in 2021, then surged by 228.46% to $2.0 million in 2022, then grew by 4.55% to $2.1 million in 2023, then surged by 299.11% to $8.5 million in 2024, then tumbled by 90.65% to $797000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $797000.0 in Q3 2025, $328000.0 in Q2 2025, and $9.0 million in Q1 2025.